Key result
Maternal reactivity to p200 autoantibodies did not confer added risk for fetal conduction defects over full-length Ro 52, with both being <50% specific for cardiac neonatal lupus.
Why the study?
Does maternal reactivity to p200 confer added risk for fetal conduction defects over full-length Ro 52 or Ro 60 autoantibodies in anti-Ro-exposed pregnancies?
Observational (n=238)
Does maternal reactivity to p200 confer added risk for fetal conduction defects over full-length Ro 52 or Ro 60 autoantibodies in anti-Ro-exposed pregnancies?
Maternal reactivity to p200 does not confer an added risk to fetal conduction defects over full-length Ro 52 or Ro 60 autoantibodies in neonatal lupus.
Authors
No takes yet. Share an insight, caveat, or question.
p200 testing adds no value for fetal risk stratification in anti-Ro pregnancies; leaves open whether refined autoantibody profiling improves cardiac neonatal lupus prediction.
Reed et al. (2012) conducted an observational in Cardiac manifestations of neonatal lupus (n=238). Maternal antibodies reactive with p200 vs. Full-length Ro 52, Ro 60, or La autoantibodies was evaluated on Cardiac manifestations of neonatal lupus. Maternal reactivity to p200 autoantibodies did not confer added risk for fetal conduction defects over full-length Ro 52, with both being <50% specific for cardiac neonatal lupus.